Artificial intelligence has been a hot area of investment for so long now that it's virtually impossible to uncover AI names that haven't seen their stock prices soar. As a result, many investors have been looking to alternative sectors where certain companies are tapping into AI technology for a variety of use cases.may be one relatively overlooked sector that's been using AI and machine learning to improve operations and uncover new treatments and products.
However, AI and machine learning could change all of that. McKinsey has identified over 250 companies working in the AI-driven drug discovery industry, which continues to grow. According to Absci, most drug discovery for biologics use existing antibody libraries to uncover improvements. However, the company recently showed how it can"design de novo antibodies 'from scratch'" via computers.
Korro has pulled together a suite of technologies and capabilities to build out its RNA editing platform using machine learning, a deep understanding of ADAR biology, expertise in oligonucleotide chemistry, and fit-for-purpose delivery.) to develop a pair of therapeutic candidates using Korro's OPERA platform. While the two targets are yet undisclosed, the candidates will be for cardiometabolic diseases.
NeuroSense recently reported positive results from its Phase 2b trial of PrimeC, which showed a statistically significant 37% slowing of disease progression in ALS.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: physorg_com - 🏆 388. / 55 続きを読む »